+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Jazz Pharmaceuticals Plc (JAZZ) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 64 Pages
  • December 2022
  • GlobalData
  • ID: 2522483
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Jazz Pharmaceuticals Plc (JAZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Jazz Pharmaceuticals Plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Defitelio (defibrotide sodium), Erwinaze (asparaginase erwinia chrysanthemi), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc Key Recent Developments

Nov 09, 2022: Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
Nov 03, 2022: Jazz Pharmaceuticals to present data at 2022 ASH meeting showcasing commitment to advancing oncology research
Oct 26, 2022: Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022
Aug 31, 2022: Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Jazz Pharmaceuticals Plc - Key Facts
  • Jazz Pharmaceuticals Plc - Key Employees
  • Jazz Pharmaceuticals Plc - Key Employee Biographies
  • Jazz Pharmaceuticals Plc - Major Products and Services
  • Jazz Pharmaceuticals Plc - History
  • Jazz Pharmaceuticals Plc - Company Statement
  • Jazz Pharmaceuticals Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Jazz Pharmaceuticals Plc - Business Description
  • Product Category: Defitelio/defibrotide
  • Overview
  • Performance
  • Product Category: Epidiolex/Epidyolex
  • Overview
  • Performance
  • Product Category: Erwinaze/Erwinase
  • Overview
  • Performance
  • Product Category: Other
  • Performance
  • Product Category: Rylaze
  • Overview
  • Performance
  • Product Category: Sativex
  • Overview
  • Performance
  • Product Category: Sunosi
  • Overview
  • Performance
  • Product Category: Vyxeos
  • Overview
  • Performance
  • Product Category: Xyrem
  • Overview
  • Performance
  • Product Category: Xywav
  • Overview
  • Performance
  • Product Category: Zepzelca
  • Overview
  • Performance
  • Product Category: Net Product Sales
  • Performance
  • Product Category: Royalties and Contract Revenue
  • Performance
  • Geographical Segment: All Other
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Jazz Pharmaceuticals Plc - Corporate Strategy
  • Jazz Pharmaceuticals Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Jazz Pharmaceuticals Plc - Strengths
  • Jazz Pharmaceuticals Plc - Weaknesses
  • Jazz Pharmaceuticals Plc - Opportunities
  • Jazz Pharmaceuticals Plc - Threats
  • Jazz Pharmaceuticals Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Jazz Pharmaceuticals Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 31, 2022: Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
  • Aug 03, 2022: Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
  • Jul 20, 2022: Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
  • Jun 01, 2022: Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference
  • May 12, 2022: Jazz Pharmaceuticals to present data showcasing clinical advancements across oncology portfolio at 2022 ASCO and EHA Meetings
  • May 03, 2022: Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference
  • Apr 20, 2022: Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
  • Mar 25, 2022: Jazz Pharmaceuticals announces significant New Investment in UK Manufacturing
  • Mar 01, 2022: Jazz Pharmaceuticals announces full year and fourth quarter 2021 financial results
  • Jan 10, 2022: Jazz Pharmaceuticals announces vision 2025 to deliver sustainable growth and enhanced value to drive transformation to innovative, global biopharmaceutical leader
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Jazz Pharmaceuticals Plc, Key Facts
  • Jazz Pharmaceuticals Plc, Key Employees
  • Jazz Pharmaceuticals Plc, Key Employee Biographies
  • Jazz Pharmaceuticals Plc, Major Products and Services
  • Jazz Pharmaceuticals Plc, History
  • Jazz Pharmaceuticals Plc, Other Locations
  • Jazz Pharmaceuticals Plc, Subsidiaries
  • Jazz Pharmaceuticals Plc, Key Competitors
  • Jazz Pharmaceuticals Plc, Ratios based on current share price
  • Jazz Pharmaceuticals Plc, Annual Ratios
  • Jazz Pharmaceuticals Plc, Interim Ratios
  • Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Jazz Pharmaceuticals Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Jazz Pharmaceuticals Plc, Performance Chart (2017 - 2021)
  • Jazz Pharmaceuticals Plc, Ratio Charts
  • Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Viracta Therapeutics Inc
  • Genentech USA Inc
  • Amgen Inc
  • Concert Pharmaceuticals Inc
  • Adamas Pharmaceuticals Inc
  • Endo International Plc
  • Biogen Inc
  • AstraZeneca Plc
  • Amgen Inc
  • Adamas Pharmaceuticals Inc
  • Viracta Therapeutics Inc
  • Genentech USA Inc
  • Biogen Inc
  • AstraZeneca Plc
  • Concert Pharmaceuticals Inc
  • Endo International Plc